DEVELOPMENT AND EVALUATION OF LULICNAZOLE NIOSOMAL TRANSDERMAL DRUG DELIVERY SYSTEM

Manasi Patharwat, Rani Ghosalkar, Kedar Bavaskar, Ashish Jain
{"title":"DEVELOPMENT AND EVALUATION OF LULICNAZOLE NIOSOMAL TRANSDERMAL DRUG DELIVERY SYSTEM","authors":"Manasi Patharwat, Rani Ghosalkar, Kedar Bavaskar, Ashish Jain","doi":"10.25004/ijpsdr.2023.150312","DOIUrl":null,"url":null,"abstract":"According to earlier research, using niosomes as drug carriers, particularly for antifungal drugs, produces greater results than using alternative carriers. Niosomes has the capacity to encapsulate both hydrophilic and hydrophobic pharmaceuticals, as well as their prolonged stability in circulation. This work aimed to prepare and evaluate luliconazole niosomal gel for antifungal activity. In this study, niosomes containing luliconazole were prepared by thin film hydration technique using non-ionic surfactant (Span 60 and Tween 80) and cholesterol at different concentrations. The prepared formulations were evaluated for optical microscopy, drug entrapment efficiency, drug content, in-vitro drug release study, and stability studies. The ratio 2:1 of span 60 and cholesterol showed better results. Hence it was optimized as the final vesicle formulation. The FTIR study concluded there was no interaction between Luliconazole and any of the excipients. The niosomes gel was evaluated for various parameters of all the formulations. The 1% Carbopol 934 gel shows the best and most promising results. The niosomal gel formulation could be a useful dosage form to increase efficacy by the transdermal route. The potential of a secure and efficient therapy for difficult clinical applications is made possible by the development of niosomes with target specificity. Therefore, niosomes gel may be considered the best vesicular carrier for the effective delivery of luliconazole through the skin.","PeriodicalId":14278,"journal":{"name":"International Journal of Pharmaceutical Sciences and Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Sciences and Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25004/ijpsdr.2023.150312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

According to earlier research, using niosomes as drug carriers, particularly for antifungal drugs, produces greater results than using alternative carriers. Niosomes has the capacity to encapsulate both hydrophilic and hydrophobic pharmaceuticals, as well as their prolonged stability in circulation. This work aimed to prepare and evaluate luliconazole niosomal gel for antifungal activity. In this study, niosomes containing luliconazole were prepared by thin film hydration technique using non-ionic surfactant (Span 60 and Tween 80) and cholesterol at different concentrations. The prepared formulations were evaluated for optical microscopy, drug entrapment efficiency, drug content, in-vitro drug release study, and stability studies. The ratio 2:1 of span 60 and cholesterol showed better results. Hence it was optimized as the final vesicle formulation. The FTIR study concluded there was no interaction between Luliconazole and any of the excipients. The niosomes gel was evaluated for various parameters of all the formulations. The 1% Carbopol 934 gel shows the best and most promising results. The niosomal gel formulation could be a useful dosage form to increase efficacy by the transdermal route. The potential of a secure and efficient therapy for difficult clinical applications is made possible by the development of niosomes with target specificity. Therefore, niosomes gel may be considered the best vesicular carrier for the effective delivery of luliconazole through the skin.
开发和评估卢立腈唑纳米透皮给药系统
根据早先的研究,使用 Niosomes 作为药物载体,尤其是抗真菌药物载体,比使用其他载体效果更好。Niosomes 既能包裹亲水性药物,也能包裹疏水性药物,而且在循环中具有长期稳定性。本研究旨在制备和评估氟硅唑的抗真菌活性。本研究使用非离子表面活性剂(Span 60 和 Tween 80)和不同浓度的胆固醇,通过薄膜水合技术制备了含有卢立康唑的niosomes。对制备的制剂进行了光学显微镜观察、药物包埋效率、药物含量、体外药物释放研究和稳定性研究。span 60 和胆固醇的比例为 2:1,结果显示效果更好。因此,它被优化为最终的囊泡配方。傅立叶变换红外光谱研究得出结论,卢利康唑与任何辅料之间都没有相互作用。对所有配方的niosomes凝胶进行了各种参数评估。1% Carbopol 934 凝胶显示出最佳和最有前景的结果。通过透皮途径增加药效,这种含糖凝胶配方可能是一种有用的剂型。具有靶向特异性的niosomes的开发为临床应用提供了安全高效的治疗潜力。因此,niosomes 凝胶可被视为通过皮肤有效递送卢利康唑的最佳囊泡载体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信